Illuminate 2024 Kick Off Meeting

The team at Illuminate enjoyed a few days at QT hotel in Newcastle, reviewing 2023 and setting up plans for 2024.
Click here to view

Illuminate moves office! (2022)

Illuminate has moved to a new office in Chatswood. Our new address is Level 13 Suite 1A, 465 Victoria Avenue, Chatswood NSW 2067.

Illuminate releases new report – 2022 Illuminate Orphan Drug Report (2022)

A unique analysis of orphan designated medicines in Australia from 2016: related PBAC decisions and PBS listings to determine their success.
See Pharma in Focus article 18 March 2022
Click here to view

Illuminate RED reaches over 15 subscribing companies (2022)

Since its launch in late 2017, there are now more than 15 subscribing pharmaceutical companies using Illuminate RED.

One of our earliest subscribing companies has this to say about Illuminate RED:

“The ease and flexibility of being able to download and combine various data sets and graphically present this, has made communicating complex data to the leadership team much easier.”

Illuminate moves new office! (2020)

Illuminate has moved to a new office in Gordon NSW. You can still find us here or in the ‘contact us’ section.

New price calculator (2017)

Illuminate has launched a new free online tool to help people calculate PBS ex manufacturers prices from dispended prices and vice versa.

Illuminate complete modelling to help determine prices for a leading global vaccine under development (2015)

This innovative work involved building several cost utility models to determine the threshold price in a range of large international markets. The vaccine is a leader in the therapeutic field. Peter also has attended the US advisory board meeting as the representative Health Economists to advise on the Phase 3 clinical trial design.

Current Projects of Interest

  • Applications to PBAC, MSAC and the Prostheses list
  • Global model for a new leading vaccine
  • Model adaptations for Asia, Europe and the Americas. Illuminate is adapting a range of budget impact and economic models for a major multinational company. Several of these were developed by Illuminate and others by another UK based consultancy.